⌘K

Login Start Free

Home/Filings/4/0001415889-25-004507

4//SEC Filing

LaBrosse Nicole 4

Accession 0001415889-25-004507

CIK 0001159036other

View on SEC.gov Company Profile

Filed

Feb 17, 7:00 PM ET

Accepted

Feb 18, 6:39 PM ET

Size

24.7 KB

Accession

0001415889-25-004507

Insider Transaction Report

Form 4

Period: 2025-02-15

HALOZYME THERAPEUTICS, INC.HALO

LaBrosse Nicole

SVP, CHIEF FINANCIAL OFFICER

Transactions

Exercise/Conversion
Common Stock
2025-02-16+5,329→ 31,682 total
Tax Payment
Common Stock
2025-02-16$58.29/sh−2,869$167,234→ 28,813 total
Exercise/Conversion
Restricted Stock Units
2025-02-15−1,254→ 0 total
Exercise: $0.00→ Common Stock (1,254 underlying)
Exercise/Conversion
Performance Stock Units
2025-02-16−17,409→ 0 total
Exercise: $0.00→ Common Stock (17,409 underlying)
Exercise/Conversion
Restricted Stock Units
2025-02-16−5,093→ 5,093 total
Exercise: $0.00→ Common Stock (5,093 underlying)
Exercise/Conversion
Restricted Stock Units
2025-02-16−5,329→ 10,658 total
Exercise: $0.00→ Common Stock (5,329 underlying)
Exercise/Conversion
Common Stock
2025-02-15+1,254→ 16,734 total
Tax Payment
Common Stock
2025-02-15$58.29/sh−741$43,193→ 15,993 total
Exercise/Conversion
Common Stock
2025-02-16+17,409→ 33,402 total
Tax Payment
Common Stock
2025-02-16$58.29/sh−9,400$547,926→ 24,002 total
Exercise/Conversion
Common Stock
2025-02-16+5,093→ 29,095 total
Tax Payment
Common Stock
2025-02-16$58.29/sh−2,742$159,831→ 26,353 total

Footnotes (6)

[F1]The reported disposition of 741 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
[F2]The reported disposition of 9,400 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
[F3]The reported disposition of 2,742 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
[F4]The reported disposition of 2,869 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
[F5]This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.
[F6]This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer.

Documents

1 file

4
form4-02182025_110210.xmlPrimary

Issuer

HALOZYME THERAPEUTICS, INC.

CIK 0001159036

Entity typeother

Related Parties

1

filerCIK 0001910662

Filing Metadata

Form type: 4
Filed: Feb 17, 7:00 PM ET
Accepted: Feb 18, 6:39 PM ET
Size: 24.7 KB

View on SEC.gov